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SHORT COMMUNICATION
AAV9-based gene therapy partially ameliorates the clinical
phenotype of a mouse model of Leigh syndrome
I Di Meo1, S Marchet1, C Lamperti1, M Zeviani2 and C Viscomi2
Leigh syndrome (LS) is the most common infantile mitochondrial encephalopathy. No treatment is currently available for this
condition. Mice lacking Ndufs4, encoding NADH: ubiquinone oxidoreductase iron-sulfur protein 4 (NDUFS4) recapitulates the main
ﬁndings of complex I (cI)-related LS, including severe multisystemic cI deﬁciency and progressive neurodegeneration. In order to
develop a gene therapy approach for LS, we used here an AAV2/9 vector carrying the human NDUFS4 coding sequence (hNDUFS4).
We administered AAV2/9-hNDUFS4 by intravenous (IV) and/or intracerebroventricular (ICV) routes to either newborn or young
Ndufs4−/− mice. We found that IV administration alone was only able to correct the cI deﬁciency in peripheral organs, whereas ICV
administration partially corrected the deﬁciency in the brain. However, both treatments failed to improve the clinical phenotype or
to prolong the lifespan of Ndufs4−/− mice. In contrast, combined IV and ICV treatments resulted, along with increased cI activity, in
the amelioration of the rotarod performance and in a signiﬁcant prolongation of the lifespan. Our results indicate that
extraneurological organs have an important role in LS pathogenesis and provide an insight into current limitations of adeno-
associated virus (AAV)-mediated gene therapy in multisystem disorders. These ﬁndings warrant future investigations to develop
new vectors able to efﬁciently target multiple organs.
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INTRODUCTION
Complex I (cI) deﬁciency accounts for ~ 30% of oxidative
phosphorylation defects1 and causes a variety of different diseases
ranging from lethal neonatal disease to adult-onset neurodegen-
erative disorders. Mammalian cI is composed of 44 different
proteins, 7 of which are encoded by mitochondrial DNA, the other
37 being encoded by the nuclear DNA. Fourteen subunits,
conserved from prokaryotes to humans, are directly involved in
the redox and proton translocating enzymatic activity, whereas 30
supernumerary subunits are involved in the assembly or regula-
tion of the complex.2–4
In humans, the ﬁrst nuclear-encoded pathogenic mutation in cI
(that is, an AAGTC duplication at position 466–470 in exon 5) was
identiﬁed in the NADH: ubiquinone oxidoreductase iron-sulfur
protein 4 (NDUFS4) subunit.5
NDUFS4 is a non-enzymatic 18 kDa nuclear-encoded subunit
that, according to the most recent cI assembly model, appears to
be incorporated at a relatively late stage.2 Mutations in the
NDUFS4 gene are associated with Leigh syndrome (LS), a fatal
progressive neurodegenerative condition of childhood character-
ized by symmetrical necrotizing lesions of the basal ganglia,
thalamus, brainstem and cerebellum. Symptoms are highly
variable, but usually include psychomotor arrest or regression,
hypotonia, dystonia, ataxia, abnormal ocular movements or
ophthalmoplegia, lethargy, apnoeic spells and respiratory
failure.6–9 Biochemically, elevated lactate levels in the blood and
cerebrospinal ﬂuid are frequently detected.10 To date, NDUFS4
mutations have been described in 22 patients from 18 families,
with symptom onset between 5 days and 4 months of life.6
A constitutive Ndufs4−/− mouse model develops a rapidly
progressive encephalopathy, starting ~ 40 days after birth,11,12
associated with severe cI deﬁciency and accumulation of a
catalytically inactive 830 kDa cI assembly intermediate. Ndufs4−/−
mouse manifests speciﬁc symptoms similar to those found in the
patients, including growth retardation, ataxia, hypotonia, lethargy,
failure to thrive and breathing irregularities. Magnetic resonance
imaging analysis reveals hyperintense lesions primarily in the
external plexiform layer of the olfactory bulb, cerebellum and
vestibular nucleus of the dorsal medulla. The severe encephalo-
pathy leads to shortened life span with > 90% mortality by
postnatal day (P) 50.13
As for the majority of mitochondrial encephalomyopathies, no
treatment is currently available for LS. Here we used an adeno-
associated virus (AAV) vector to deliver human NDUFS4 (hNDUFS4)
in Ndufs4−/− mice and test proof-of-principle feasibility and
efﬁcacy of a gene therapy strategy aimed to ameliorate the
clinical and biochemical phenotype of an otherwise fatal
mitochondrial encephalomyopathy.
RESULTS
Systemic AAV2/9-hNDUFS4 is widely distributed in adult mouse
tissues, restores cI assembly and activity in peripheral tissues but
does not ameliorate the clinical phenotype in Ndufs4−/− mice
In order to develop a suitable vector for gene therapy in Leigh
disease, a multisystem mitochondrial disease, we cloned the human
wild-type NDUFS4 cDNA (hNDUFS4) into a single-stranded AAV2/9
viral vector under the control of the strong, general promoter of the
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cytomegalovirus (CMV) (AAV2/9-hNDUFS4) (Figure 1a). AAV9 has a
wide tropism, which allows it to infect several tissues. This feature
makes it a strong candidate for gene therapy in multisystem
disorders. The hNDUFS4 protein is almost identical to the mouse
(m)NDUFS4 protein (88% identity; 94% similarity), displaying 22
changes, 14 of which occur in the predicted mitochondrial targeting
sequence at the N terminus (Figure 1b). We initially administered
2×1012 viral genomes (vg)/mouse intravenously (IV) by retroorbital
IV injection in two Ndufs4−/− mice at P21 and investigated the tissue
distribution of the viral particles and the correct processing and
incorporation of the mature hNDUFS4 protein into mouse cI.
Western blot immunovisualization with an anti-NDUFS4 antibody
showed high expression levels of hNDUFS4 protein in skeletal
muscle (gastrocnemius), heart and liver, but not in the brain
(Figure 2a), suggesting that AAV2/9 vector was unable to cross the
adult brain–blood barrier after IV injection. Interestingly, we
observed a difference in the apparent molecular weight between
the endogenous mNDUFS4 and the transduced hNDUFS4 proteins,
as previously reported.14 Comparison of the antibody-detected
bands in homogenates from Ndufs4+/+, AAV-transduced Ndufs4−/−
mouse livers and human control ﬁbroblasts conﬁrmed that the
human and mouse proteins had different molecular weights
(Figure 2b). However, AAV-transduced hNDUFS4 was able to fully
restore cI assembly in Ndufs4−/− liver mitochondria (Figure 2c) and
to rescue the cI spectrophotometric activity (Figure 1e) in all tissues
(Figure 2d). No obvious differences in body weight and motor
coordination by rotarod test were observed in treated vs untreated
Ndufs4−/− littermates (n=3) (Supplementary Figure 1). Similarly, the
survival probability was similar between treated and untreated
animals (survival median: naïve Ndufs4−/− 55.0 days; AAV-treated
Ndufs4−/− 58.0 days).
Systemic AAV2/9-hNDUFS4 does not ameliorate the clinical
phenotype of Ndufs4−/− newborn mice
It was previously reported that AAV2/9 can cross the brain–blood
barrier when injected systemically into newborns.15,16 To this end,
and in order to anticipate the treatment before the onset of the
neuro-muscular symptoms, we IV injected 1 × 1012 (IV-L) and
2× 1012 (IV-H) vg per mouse in two groups of three newborn
Ndufs4−/− mice through the temporal vein. Both IV-L- and IV-H-
injected animals showed no differences in body weight (Figure 3a)
and in motor coordination (Figure 3b), compared with untreated
Ndufs4−/− littermates. Moreover, the two IV injections did not
prolong the lifespan of treated vs untreated Ndufs4−/− mice
(survival median IV-L: 53.0 days; IV-H: 51.0 days) (Figure 3c).
Real-time quantitative PCR analysis revealed the presence of AAV
viral DNA in the brain (IV-L: 0.44 ± 0.13 vg per cell; IV-H: 0.89 ± 0.16
vg per cell), muscle (IV-L: 1.62 ± 0.57; IV-H: 2.82 ± 0.52), heart (IV-L:
10.71 ± 1.47; IV-H: 15.72 ± 1.71) and liver (IV-L: 52.01 ± 11.34; IV-H:
84.28 ± 9.51) (Figure 3d). Western blot analysis on autoptic tissues
revealed expression of hNDUFS4 protein in muscle and heart of
AAV-transduced Ndufs4−/− mice (~50% of Ndufs4+/+), whereas no
hNDUFS4-crossreacting material was detected in the brain and
liver (Figure 3e). Although low transduction efﬁciency in the brain
could justify the low protein levels, the lack of protein in the liver
in the presence of extremely high viral DNA and hNDUFS4 mRNA
(not shown) suggests a posttranscriptional silencing of the
transduced gene. However, we found a remarkable correction of
cI activity defect in the skeletal muscle and heart, whereas no
signiﬁcant effect was observed in both brain and liver. In
particular, cI/citrate synthase activity in skeletal muscle was
increased from 8% in Ndufs4−/− mice to 39% in IV-L- and to 57%
in IV-H-treated mice. Similarly, cI/citrate synthase in heart
increased from 11% to 46% and 68% in IV-L and IV-H, respectively
(Figure 3f).
ICV injections of AAV2/9-hNDUFS4 slightly ameliorate the clinical
phenotype in newborn Ndufs4−/− mice
In order to bypass the brain–blood barrier ﬁlter, we performed
intracerebroventricular (ICV) injections of AAV2/9-hNDUFS4 using
1.5 × 1011 (ICV-L) and 3 × 1011 (ICV-H) vg per mouse in two groups
of newborn (P1) Ndufs4−/− mice (n= 3). At both dosages injected
Figure 1. AAV2/9-CMV-hNDUFS4. (a) Schematic representation of
AAV2/9-CMV-hNDUFS4 vector. BGH pA, bovine growth hormone
polyadenilation signal; CMV, cytomegalovirus promoter; hNDUFS4,
human NDUFS4 coding sequence; ITR, inverted terminal repeats;
WPRE, woodchuck hepatitis virus posttranscriptional regulatory
element. (b) Sequence alignment of Human vs Mouse NDUFS4
proteins. The grey line indicates the predicted mitochondrial
targeting sequence. Letters on black background: identities; letters
on grey background: similarities; letters on white background:
mismatches. Gray arrows show the position of missense mutations
found in patients.
Figure 2. Molecular characterization of AAV2/9-CMV-hNDUFS4 IV-
treated adult mice. A single retroorbital injection of 2 × 1012 vg was
performed in Ndufs4−/− mice at P21. (a) Western blot analysis of
tissue homogenates. (b) Comparison of Ndufs4+/+ liver, Ndufs4−/−
AAV-treated liver and human ﬁbroblasts (hFib) homogenates. SDH-
A, the 70 kDa subunit of succinate dehydrogenase was used as
protein-loading standard. (c) Blue-native gel electrophoresis on liver
mitochondria from untreated and AAV-treated Ndufs4−/− mice.
(d) Viral genome copies (gc) content in tissues from AAV-treated
Ndufs4−/− mice (n= 3). Bars indicate the s.d. (e) Complex I activity in
tissues from Ndufs4−/− (red; n= 6) and AAV-treated Ndufs4−/− mice
(blue; n= 3) normalized against Ndufs4+/+ mice (dashed line; n= 6)
activity, expressed as percentage of cI/citrate synthase (CS). Bars
indicate s.d. The asterisks represent the signiﬁcance levels calculated
by unpaired, Student’s two-tailed t-test: *Po0.05, **Po0.01 and
***Po0.001.
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Figure 3. Molecular and clinical characterization of AAV2/9-CMV-hNDUFS4 IV-treated newborn mice. (a) Variation of body weights over time in
Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV IV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H-treated Ndufs4−/− (green; n= 3) mice.
Error bars represent s.d. (b) Rotarod analysis in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV IV-L-treated Ndufs4−/− (blue; n= 3) and
AAV IV-H-treated Ndufs4−/− (green; n= 3) mice. Error bars represent SD. (c) Kaplan–Meier survival probability in Ndufs4+/+(white outline; n= 6),
Ndufs4−/− (red; n= 6), AAV IV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H-treated Ndufs4−/− (green; n= 3). (d) Viral gc content in tissues from
AAV IV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H-treated Ndufs4−/− (green; n= 3). Error bars represent s.d. (e) Western blot analysis of tissue
homogenates. SDH-A was used as protein-loading standard. (f) Complex I activity in tissues from Ndufs4−/− (red; n= 6) AAV IV-L-treated
Ndufs4−/− (blue; n= 3) and AAV IV-H-treated Ndufs4−/− (green; n= 3) normalized against Ndufs4+/+ mice (dashed line; n= 6), expressed as
percentage of cI/citrate synthase (CS). Bars indicate s.d. The asterisks represent the signiﬁcance levels calculated by unpaired, Student’s
two-tailed t-test: *Po0.05, **Po0.01 and ***Po0.001.
Figure 4. Molecular and clinical characterization of AAV2/9-CMV-hNDUFS4 ICV-treated newborn mice. (a) Variation of body weights over time
in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV ICV-H-treated Ndufs4−/− (green; n= 3)
mice. Error bars represent s.d. (b) Rotarod analysis in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV ICV-L-treated Ndufs4−/− (blue;
n= 3) and AAV ICV-H-treated Ndufs4−/− (green; n= 3) mice. Error bars represent s.d. The asterisks represent the signiﬁcance levels vs untreated
Ndufs4−/− mice calculated by unpaired, Student’s two-tailed t-test: *Po0.05, **Po0.01 and ***Po0.001. (c) Kaplan–Meier survival probability
in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV ICV--–treated Ndufs4−/− (blue; n= 3) and AAV ICV-H-treated Ndufs4−/− (green; n= 3).
(d) Viral gc content in tissues from AAV ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV ICV-H-treated Ndufs4−/− (green; n= 3). Error bars represent
s.d. (e) Western blot analysis of tissue homogenates. SDH-A was used as protein-loading standard. (f) Complex I activity in tissues from
Ndufs4−/− (red; n= 6) AAV ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV ICV-H-treated Ndufs4−/− (green; n= 3) normalized against Ndufs4+/+ mice
(dashed line; n= 6), expressed as percentage of cI/citrate synthase (CS). Bars indicate s.d. The asterisks represent the signiﬁcance levels
calculated by unpaired, Student’s two-tailed t-test: *Po0.05, **Po0.01 and ***Po0.001.
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animals showed no signiﬁcant differences in body weights.
However, ICV-H-injected mice resulted in a slight increase in body
weight (Figure 4a) and in a signiﬁcant improvement in motor
coordination at rotarod test (Figure 4b), not present in ICV-L
animals. In addition, both ICV treatments failed to prolong the
lifespan of injected animals (survival median ICV-L: 55.0; ICV-H:
60 days) (Figure 4c). AAV9 DNA (ICV-L: 2.42 ± 0.4 vg per cell; ICV-H:
4.3 ± 0.32 vg per cell) and hNDUFS4 protein were present in the
brains of all injected animals (Figures 4d and e) and, accordingly,
cI activity increased from 8% in Ndufs4−/− untreated animals to
42 and 65% in ICV-L- and ICV-H-treated mice, respectively
(Figure 4f).
Double IV+ICV injections in newborns of AAV2/9-hNDUFS4
ameliorate the clinical phenotype and increases lifespan of
Ndufs4−/− mice
Owing to the multisystemic phenotype of Ndufs4−/− mouse model,
we reasoned that IV/ICV double treatment could be more effective
in ameliorating Ndufs4−/− mouse phenotype. We performed IV-H
injection coupled with ICV-L (IV-H/ICV-L) and ICV-H (IV-H/ICV-H) in
two groups of newborn Ndufs4−/− mice (n= 3). Although IV-H/ICV-
L-injected animals showed no differences in body weight and
motor coordination, IV-H/ICV-H-injected animals resulted in
increased body weight (Figure 5a) and in a highly signiﬁcant
improvement in motor coordination (Figure 5b). A moderate but
signiﬁcant prolongation of the survival probability was also
observed (survival median IV-H/ICV-L: 53.5; IV-H/ICV-H: 82 days)
(Figure 5c). Western blot analysis revealed that hNDUFS4 protein
was present in the brain, muscle and heart (Figure 5e) of all IV-H/
ICV-H mice, in agreement with the tissue distribution of the viral
DNA (with the exception of the liver as reported above)
(Figure 5d). Accordingly, cI activity was restored to wild-type
levels in the muscle and heart, and to 70% of controls in the brain
(Figure 5f).
Given the impossibility to detect hNDUFS4 protein by
immunoﬂuorescence, we used an AAV2/9-CMV-eGFP vector as a
proxy to evaluate the distribution of the viral vector in the brain
tissue. Immunoﬂuorescence analysis of coronal brain sections
from wild-type mice ICV-injected with 2 × 1010 vg per mouse
revealed abundant green ﬂuorescence protein (GFP) signal in
several areas of the brain, including the olfactory bulb (Figure 6e),
the lower layers of motor cortex (Figure 6g), the hippocampus
(Figure 6h) and the Purkinje cells in the cerebellum (Figure 6k). A
particularly strong signal was detected in the piriform cortex
(Figure 6i). On the contrary, only few GFP-positive cells were
detected in the striatum (Figure 6f), thalamus (Figure 6j) and
vestibular nuclei (Figure 6l). In addition, in all areas GFP-positive
cells do not colocalize with the neuron-speciﬁc marker NeuN,
suggesting that glial cells are the main target of this vector.
These data suggest that the partial rescue of the phenotype is
likely related to the uneven distribution of the virus in the brain
parenchyma.
DISCUSSION
AAV-mediated gene therapy has been extensively used in
pre-clinical and clinical studies for the treatment of neuromuscular
disorders.17,18 Here we tested the feasibility and efﬁcacy of an
AAV-based strategy on the Ndufs4−/− mouse, a model of LS, a
prototypical mitochondrial encephalomyopathy.
In this study, we used the hNDUFS4 gene to rescue the murine
phenotype. The human and murine proteins are highly conserved,
although a slight difference of about 1 kDa in the molecular
weight suggests a different cleavage, as previously reported for
the bovine vs murine proteins.14 However, this does not impact
Figure 5. Molecular and clinical characterization of AAV2/9-CMV-hNDUFS4 IV-H/ICV-treated newborn mice. (a) Variation of body weights over
time in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV IV-H/ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H/ICV-H-treated Ndufs4−/−
(green; n= 3) mice. Error bars represent s.d. (b) Rotarod analysis in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV IV-H/ICV-L-treated
Ndufs4−/− (blue; n= 3) and AAV IV-H/ICV-H-treated Ndufs4−/− (green; n= 3) mice. Error bars represent s.d. The asterisks represent the
signiﬁcance levels vs untreated Ndufs4−/− mice calculated by unpaired, Student’s two-tailed t test: *Po0.05, **Po0.01 and ***Po0.001.
(c) Kaplan–Meier survival probability in Ndufs4+/+(white outline; n= 6), Ndufs4−/− (red; n= 6), AAV IV-H/ICV-L-treated Ndufs4−/− (blue; n= 3) and
AAV IV-H/ICV-H-treated Ndufs4−/− (green; n= 3). (d) Viral gc content in tissues from AAV IV-H/ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H/
ICV-H-treated Ndufs4−/− (green; n= 3). Error bars represent s.d. (e) Western blot analysis of tissue homogenates. SDH-A was used as protein-
loading standard. (f) Complex I activity in tissues from Ndufs4−/− (red; n= 6) AAV IV-H/ICV-L-treated Ndufs4−/− (blue; n= 3) and AAV IV-H/ICV-H-
treated Ndufs4−/− (green; n= 3) normalized against Ndufs4+/+ mice (dashed line; n= 6), expressed as percentage of cI/citrate synthase (CS). Bars
indicate s.d. The asterisks represent the signiﬁcance levels calculated by unpaired, Student’s two-tailed t-test: *Po0.05, **Po0.01 and
***Po0.001.
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the function since the human protein can fully rescue the cI defect
in mouse liver.
The Ndufs4−/− mouse model is characterized by reduced cI
activity in all tissues, although a prevalent neurological compo-
nent has been reported.13 Accordingly, systemic administration of
viral particles in both adults and newborn mutant animals was
unable to correct the clinical phenotype, although a marked
correction of cI deﬁciency was observed in muscle and heart, the
most affected tissues outside the CNS in early-onset cI encepha-
lomyopathies. Interestingly, the liver was the organ with the
highest viral copy number, robust expression of the recombinant
transcript, but hardly any trace of Ndufs4 protein in newborn
mice. However, Ndufs4 was readily detectable in animals injected
at P21, suggesting the existence of a silencing mechanism
restricted to the neonatal period, that inhibits hepatic translation
of the recombinant gene. The elucidation of this mechanism
warrants additional work in the future. Although a number of
studies showed that recombinant AAV2/9 can cross the brain–
blood barrier at least in newborn mice,19 we were unable to detect
viral DNA, or the transduced mRNA/protein, in the brains of
animals treated by IV injection only, either newborn or adults.
ICV administration of AAV2/9-hNDUFS4 led to a moderate
improvement of the clinical phenotype, in spite of relatively high
hNDUFS4 expression levels and restoration of cI activity up to 75%
of the norm. In contrast, double administration of AAV particles by
both IV and ICV routes led to a remarkable improvement of the
clinical signs, such as gain in body weight and amelioration in
motor coordination, and highly signiﬁcant prolongation of the
lifespan compared with untreated Ndufs4−/− mice. Palmiter and
colleagues13 demonstrated that the Ndufs4−/− model shows brain
lesions mainly at level of olfactory bulbs, cerebellum and
vestibular nuclei. Although the experiments with the GFP reporter
showed a relatively good distribution of the virus and an
improvement of cI activity in olfactory bulbs and cerebellum
assessed by histochemical analysis, ICV injection of our AAV2/9
was unable to efﬁciently transduce vestibular nuclei, striatum and
thalamus, which are critical brain structures in LS. The low
transduction efﬁciency of basal ganglia, thalamus and striatum
may explain the progressive, albeit slower, neurological disease
course observed in treated mice. Notably, the GFP-based
distribution of AAV2/9 in the brain seems to be restricted or
predominant to glial cells, suggesting that correction of oxidative
phosphorylation defects in these cell types has a protective effect
Figure 6. Immunoﬂuorescence analyses on AAV2/9-CMV-eGFP ICV-treated newborn wild-type mouse brain. Newborn wild-type mouse were
ICV injected with 2 × 1010 vg per mouse. Images showed AAV distribution at P60. (a–d) Double-staining with anti-GFP (green) and the nuclear
marker TO-PRO3 (blue) on reconstructed brain coronal sections. (e–l) Double-staining with anti-GFP (green) and anti-NeuN (red) on different
brain areas: (e) olfactory bulb, (f) striatum, (g) motor cortex, (h) hippocampus, (i) piriform cortex, (j) thalamus, (k) cerebellum, (l) vestibular
nuclei of medulla. Scale bar: 200 μm.
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on neurological functions and possibly on neuronal survival as
well. This view is concordant with previous observations20 that the
selective deletion of Tfam restricted to neurons, using the
(neonatal) CamKII promoter, which is not active in glial cells, is
associated with prolonged survival for several months after birth,
before catastrophic neurodegeneration ensues. The beneﬁcial
effects obtained in individuals treated with combined IV and ICV
injections suggests that correction of cI defects in extraneurolo-
gical organs is an important component of the overall improve-
ment in motor performance and lifespan.
In conclusion, this study warrants further development of
suitable vectors able to determine a more even and robust
transduction of critical brain areas. New AAV serotypes recently
isolated by capsid selection method seem to be very promising to
this end.21
MATERIALS AND METHODS
Reagents
Antibodies (NDUFA9, SDHA, CORE1) were from Mitosciences
(Cambridge, UK), NDUFS4 and GFP were from Abcam (Cambridge,
UK) and NeuN was from Millipore (Vimodrone (MI), Italy).
Animals
All procedures were approved by the Italian Ministry of Health and
local ethical review, in accordance with the Italian Law D.L.
26/2014 and the EU directive 2010/63/EU. The mice were kept on
a C57Bl6/129Sv mixed background, and wild-type littermates were
used as controls. The animals were maintained in a temperature-
and humidity-controlled animal-care facility with a 12 h light/dark
cycle and free access to water and food, and were killed by
cervical dislocation. Body weight was monitored twice a week.
Vector construction, production and injection
hNDUFS4 was PCR ampliﬁed, cloned into the Pcr2.1 TOPO vector
(Thermoﬁsher Scientiﬁc, Monza, Italy), sequence veriﬁed and
ﬁnally cloned into the rAAV2-CMV vector. Recombinant AAV2/9-
CMV-hNDUFS4 and AAV2/9-CMV-eGFP vector particles were
generated using HEK293 cells grown in serum-free suspension
conditions in shaker ﬂasks, using proprietary methods developed
at the UNC Gene Therapy Center Vector Core facility (Chapel Hill,
NC, USA).22 AAV titer was obtained by both dot blot and
quantitative PCR. In adult mice, AAV particles were administered
systemically by retroorbital injection.23 ICV and IV neonatal
injections were performed as previously described.24 For ICV
injection, pups were injected with 2–4 μl AAV2/9–CMV–hNDUFS4
or AAV2/9-CMV-eGFP into the lateral ventricle of each hemisphere,
located 1 mm lateral to the superior sagittal sinus and 2 mm
rostral to the transverse sinus, to a depth of 2 mm, using an
electrophysiology glass capillary connected to a sterile syringe. For
IV injections, pups were injected with 25–50 μl AAV particles into
the temporal vein, using a 31-gauge, 30° beveled needle syringe.
Rotarod analysis
A rotarod apparatus (Ugo Basile, Varese, Italy) was used to assess
coordination skills. After two acclimation sessions, the mice
underwent three trial sessions at least 20 min apart, using a
standard acceleration protocol pre-set by the constructor.
Immunoblotting
Mouse tissues were homogenized in 10 volumes of 10 mM
potassium phosphate buffer (pH 7.4). Mitochondrial-enriched
fractions were collected after centrifugation at 800 g for 10 min
in the presence of protease inhibitors, and frozen and thawed
three times in liquid nitrogen. Protein concentration was
determined by the Lowry method. Aliquots, 70 μg each, were
run through a 12% SDS-polyacrylamide gel electrophoresis and
electroblotted onto a nitrocellulose membrane, which was then
immunodecorated with different antibodies.
For blue native gel electrophoresis analysis, liver mitochondria
isolated as previously described25 were resuspended in 1.5 M
aminocaproic acid, 50 mM Bis-Tris-HCl pH 7 and 1.6 mg dodecyl-
maltoside per mg of proteins, and incubated for 5 min on ice
before centrifuging at 20 0003 g at 4 °C. Coomassie G250 (5%) was
added to the supernatant. One hundred micrograms were
separated by 3–12% gradient blue native gel electrophoresis
and then electroblotted on nitrocellulose membranes for
immunodetection.
Genome DNA extraction and quantitative PCR
Total DNA was extracted from frozen tissues. SYBR-GREEN-based
real-time quantitative PCR Invitrogen (Monza (MB), Italy) was
carried out for AAV-copy number analysis as previously
described26 using primers speciﬁc to both human and murine
NDUFS4 genes; the RNAseP gene was used as a reference.
Biochemical analysis
Tissues were snap-frozen in liquid nitrogen and homogenized in
10 mM phosphate buffer (pH 7.4). The spectrophotometric activity
of cI, as well as citrate synthase, was measured as previously
described.27
Immunoﬂuorescence analysis
Brains from AAV2/9-CMV-eGFP-injected animals were post-ﬁxed in
paraformaldehyde 5% for 24 h at 4 °C, crioprotected in phosphate-
buffered saline containing 30% sucrose for 48 h at 4 °C and then
frozen in optimal cutting temperature compound in dry ice.
Twenty-micrometer-thick cryostat sections mounted on gelati-
nated glass slices were incubated with rabbit anti-GFP (1:1000)
and mouse anti-NeuN (1:1000). After washing the sections three
times with phosphate-buffered saline, they were stained with
Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000, Invitro-
gen, Monza (MB), Italy), Alexa Fluor 568-conjugated goat anti-
mouse (1:1000, Invitrogen) and TO-PRO-3 nucleic acid stain
(1:1000, ThermoFisher, Monza (MB), Italy). Finally, the sections
were examined using a TCS-SP8 laser confocal microscope (Leica,
Buccinasco (MI), Italy).
Statistical analysis
All numerical data are expressed as mean± s.d. Student’s unpaired
two-tail t-test and Kaplan–Meier distribution were used for
statistical analysis. Differences were considered statistically
signiﬁcant for Po0.05.
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